FDA Accepts ReNu BLA for Knee OA; Organogenesis Sets April 2027 PDUFA Date
ORGO sits 23% above its 52-week low of $2.04.
Summary
The FDA has accepted Organogenesis' Biologics License Application (BLA) for ReNu®, a treatment designed for symptomatic knee osteoarthritis, and has set a PDUFA target action date of April 24, 2027. This regulatory milestone is particularly significant for the company, which previously reported a 57% year-over-year revenue decline and a widened net loss in Q1 2026, attributed to CMS reimbursement changes. The potential approval of ReNu®, which targets a substantial market of approximately 31 million Americans, could introduce a crucial new revenue stream and aid in diversifying Organogenesis' product portfolio. The market's attention will now be directed towards the April 2027 PDUFA date for the FDA's final decision.
At the time of this announcement, ORGO was trading at $2.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $319.1M. The 52-week trading range was $2.04 to $7.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.